My research interests during more than 40 years in both the academic and corporate arenas have included: applications of low temperature in medicine and surgery; in vitro preservation of transplantable tissues; prevention of ischemic injury in vivo, with emphasis on hypothermic neuroprotection and myocardial preservation; mechanisms of cryoinjury in multicellular tissues with an emphasis on the development of ice-free methods of cryopreservation. These research activities have culminated in the publication of more than 200 peer-reviewed papers and patents in the field of low temperature biology and medicine. My standing in the field was recognized in 2010 by award of the Luyet Medal and election as a Fellow of the international Society for Cryobiology, which is a peer appointment awarded to those who have demonstrated sustained life-­long contribution to the science and field of Cryobiology and Cryomedicine. I am the inventor on record of successfully commercialized low temperature preservation solutions for mammalian tissues including Hypothermosol® (Marketed by Biolife Solutions Inc.) and Unisol® (Organ Recovery Systems, Inc.). I also played a major role in the development of the world leading organ transport system LifePort®. This FDA approved platform, now serving over 300 major transplant programs in 39 countries with over 112,000 clinical procedures successfully performed, allowed a successful IPO for Organ Recovery Systems, Inc. HypoThermosol® (HTS) and CryoStor® (HTS + Cryoprotectant) platform of solutions are proprietary solutions marketed by BioLife Solutions, Inc and are highly valued in the regenerative medicine, biobanking and drug discovery markets. These biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death; offering commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function (https://www.biolifesolutions.com/)